Cardiff Oncology, Inc. (CRDF) — Institutional Holders, Q2 2026 (page 2)
105 institutional investment managers reported a CRDF position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $24.2M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 105. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
CRDF 13F holders ranked 101–105 of 105
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 101 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT#101 · 48 sh | 48 | $62.00 | 0.00% | 0.0% |
| 102 | Parallel Advisors#102 · 35 sh | 35 | $46.00 | 0.00% | New |
| 103 | Caitong International Asset Management , Ltd#103 · 5 sh | 5 | $6.00 | 0.00% | -100.0% |
| 104 | Front Row Advisors#104 · 1 sh | 1 | $1.00 | 0.00% | New |
| 105 | ROSS\JOHNSON & Associates#105 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.